27th July 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

USFDA identified quality issues at Glenmark Pharma's Baddi facility

The American market-focused Baddi facility of Glenmark Pharmaceuticals Ltd. has been identified as having quality control and operational flaws. After completing its inspection at the non-sterile finished drugmaking facility USFDA issued a Form 483 with six observations.

A special dividend of ₹193 per equity share declared once by Sanofi

For the fiscal year ending December 31, 2022, pharmaceutical company Sanofi India declared a one-time special interim dividend of ₹193 per equity share. The company has released its second quarterly report for the year, showing a sequential and annual fall in both net profit and revenue.

Indian pharma firms projected to witness limited revenue growth from US generics market in FY23: ICRA

Due to ongoing pricing pressure, the absence of significant generic product releases, and heightened regulatory scrutiny, the revenues from the US market have expanded at a relatively slow rate.

DoP accepting submissions under PLI scheme for producing vitamin B1

The production linked incentive (PLI) scheme for the creation of vitamin B1 by chemical synthesis has been extended by the Department of Pharmaceuticals (DoP) to qualifying API producers throughout the nation.

Govt shortly going to rationalize the trade margin for unscheduled pharmaceuticals

The government intends to rationalize trade margins on non-scheduled medications in the near future. The pharmaceutical sector and government organizations have met extensively to discuss trade margin optimization in order to ensure affordable access to quality healthcare.

Sun Pharma extends its partnership with Cassiopea for acne cream to six new markets

Sun Pharmaceutical Industries said that it has broadened the scope of its collaboration with Cassiopea on an acne medicine. In order to expand the territory, it has signed addendum to the licence and supply agreements for WINLEVI (clascoterone) cream 1%.

Serum Institute seeking collaborators to create monkeypox vaccine

The largest manufacturer of vaccines in the world, Serum Institute of India (SII), has started talking with potential collaborators about creating a vaccine for monkeypox. The CEO of SII reported that he was in discussions with possible vaccine-development partners.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?